# Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors

> **NCT05851092** · PHASE1 · UNKNOWN · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** HRS-2189 Tablets

## Key facts

- **NCT ID:** NCT05851092
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05851092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05851092, "Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05851092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*